AAB-001 (bapineuzumab)(老年癡呆症治療藥物):開發平台分析及市場預測

本報告提供老年癡呆症治療藥物 AAB - 001 的開發平台評估及市場預測，以市場特徵為首，評估分析競爭，開發平台等，加進未來市場競爭預測，為您概述為以下內容。

1目錄

• 1.1 表格一覽
• 1.2 圖表一覽

2 簡介

• 2.1 老年癡呆症
• 2.2 症狀
• 2.3 老年癡呆症市場
• 2.4 流行病學
• 2.5 病因論
• 2.5.1 年齡
• 2.5.2 家族病史
• 2.5.3 遺傳學
• 2.6 經濟影響; 老年癡呆症
• 2.7 GlobalData 報告指南

3 老年癡呆症:市場特性

• 3.1 老年癡呆症市場
• 3.2 老年癡呆症 市場預測 及 年複合成長率
• 3.3 老年癡呆症治療藥物推動市場成長要素及障礙
• 3.3.1 老年人口
• 3.3.2 專利期間的結束
• 3.3.3 新商品發售
• 3.3.4 未滿足需求高

4 老年癡呆症的分類

• 4.1 階段1(輕度)
• 4.2 階段2(中度)
• 4.3 階段3(重度)

5 老年癡呆症的治療方法

• 5.1 癡呆症書
• 5.1.1 膽鹼酯酶抑制劑(ChEIs)
• 5.1.2 NMDA 拮抗劑
• 5.1.3 其他 藥物療法藥
• 5.2 行動上的症狀 及 心理障礙
• 5.2.1 非藥理學的處置方法
• 5.2.2 處方藥
• 5.3 新一代藥
• 5.3.1 預防維護藥
• 5.3.2 根據時間常數決定方向的治療
• 5.3.3 其他治療

6 AAB - 001

• 6.1 簡介
• 6.2 作用機制
• 6.3 臨床研究
• 6.3.1 從輕度到中度的老年癡呆症(ApoE4 非擁有者及 ApoE4 擁有者)的患者 Bapineuzumab (AAB - 001)，第二階段
• 6.3.2 從輕度到中度的老年癡呆症(ApoE4 非擁有者的)患者的AAB - 001，第三階段
• 6.4 AAB - 001銷售額的影響因素
• 6.4.1 有改用可能性的疾病
• 6.4.2 免疫疾病療法劃時代的醫藥品
• 6.4.3 現有的上市藥專利期的結束
• 6.4.4 其他AAB - 001用量決策形態的臨床實驗
• 6.4.5 FDA的迅速規定情勢
• 6.4.6 LY2062430 競爭
• 6.5 藥物評估
• 6.5.1 藥物風險·效益評估
• 6.5.2 競爭的強度
• 6.6 銷售預測
• 6.6.1 目標患者群-AAB-001
• 6.6.2 投藥
• 6.6.3 市場普及率
• 6.6.4 AAB - 001銷售額預測

7 附錄

• 7.1 市場定義
• 7.2 簡稱
• 7.3 研究調查方法
• 7.3.1 調查範圍
• 7.3.2 二級研究
• 7.3.3 預測
• 7.3.4 核可服用的患者數
• 7.3.5 藥物的純普及率
• 7.3.6 年度淨用藥量
• 7.3.7 治療的年度成本
• 7.4 藥物銷售額預期模式
• 7.5 諮詢方式
• 7.6 免責聲明
• 7.7 資訊來源

表格一覽

1.1 表格一覽

• 表格1: 老年癡呆症，全球、 第三階段 的 主要 開發中產品
• 表格2:輕度階段 受到老年癡呆症、 影響的身體能力及其典型性的症狀
• 表格3:中等度階段 受到老年癡呆症、 影響的身體能力及其典型性的症狀
• 表格4:重度階段 受到老年癡呆症、 影響的身體能力及其典型性的症狀
• 表格5:行動性症狀及 心理障礙 非藥理學的處置方法
• 表格6:老年癡呆症 第三階段 的緩和疾病藥物(第二線藥物)
• 表格7: AAB - 001，第二階段臨床實驗結果
• 表格8: AAB - 001，老年癡呆症，藥物風險·效益評估
• 表格9: AAB - 001，全球市場 老年癡呆症、 銷售額 預測 (m美元)，預測
• 表格10: AAB - 001，老年癡呆症，美國、 銷售額 預測 (m美元)，預測
• 表格11: AAB - 001，老年癡呆症，英國、 銷售額 預測 (m美元)，預測
• 表格12: AAB - 001，老年癡呆症，法國、 銷售額 預測 (m美元)，預測
• 表格13: AAB - 001，老年癡呆症，德國、 銷售額 預測 (m美元)，預測
• 表格14: AAB - 001，老年癡呆症，義大利、 銷售額 預測 (m美元)，預測
• 表格15: AAB - 001，老年癡呆症，西班牙、 銷售額 預測 (m美元)，預測
• 表格16: AAB - 001，老年癡呆症，日本、 銷售額 預測 (m美元)，預測

圖表一覽

Abstract

AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022

Summary

GlobalData's pharmaceuticals report, "AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022" provides AAB-001 global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2022). The report also includes information on Alzheimer's disease market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of AAB-001 including sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of AAB-001 including efficacy, safety, pricing, competition and other details which influence its sales potential
• Global sales forecast for 2014-2022 for AAB-001

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug's performance
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

Keywords

AAB-001, bapineuzumab, anti-amyloid monoclonal antibody, Johnson & Johnson, Pfizer, Alzheimer's disease

TOC

1 Table of Contents

1 Table of Contents 2

• 1.1 List of Tables 3
• 1.2 List of Figures 3

2 Introduction 4

• 2.1 Alzheimer's Disease 4
• 2.2 Symptoms 5
• 2.3 Alzheimer's disease Market 5
• 2.4 Epidemiology 5
• 2.5 Etiology 7
• 2.5.1 Age 7

2.5.2 Family History 7

• 2.5.3 Genetics 7
• 2.6 Economic Impact of Alzheimer's disease 8
• 2.7 GlobalData Report Guidance 9

3 Alzheimer's disease: Market Characterization 10

• 3.1 Alzheimer's disease Market 10
• 3.2 Alzheimer's disease Market Forecasts and CAGR 10
• 3.3 Drivers and Barriers of Alzheimer's disease Therapeutics Market 11
• 3.3.1 Ageing Population 11
• 3.3.2 Patent Expiries 11
• 3.3.3 New Product Launches 12
• 3.3.4 High Unmet Need 12

4 Classification of Alzheimer's disease 13

• 4.1 Stage 1 (Mild) 13
• 4.2 Stage 2 (Moderate) 13
• 4.3 Stage 3 (Severe) 14

5 Treatment for Alzheimer's disease 15

• 5.1 Cognitive Symptoms 15
• 5.1.1 Cholinesterase Inhibitors (ChEIs) 15
• 5.1.2 NMDA antagonists 15
• 5.1.3 Other Pharmacotherapeutic Agents 16
• 5.2 Behavioural Symptoms and Mood Disorders 16
• 5.2.1 Non-pharmacological Approaches 16
• 5.2.2 Prescription Medicines 17
• 5.3 Next-generation Drugs 17
• 5.3.1 Disease Modifying Agents 17
• 5.3.2 Tau-directed Therapies 18
• 5.3.3 Other Therapies 18

6 AAB-001 19

• 6.1 Introduction 19
• 6.2 Mechanism of Action 19
• 6.3 Clinical Studies 19
• 6.3.1 Bapineuzumab (AAB-001) in Patients with Mild to Moderate Alzheimer's disease (ApoE4 Non-Carrier & ApoE4 Carrier), Phase - II 19
• 6.3.2 Phase III AAB-001 in Patients with Mild to Moderate Alzheimer's disease (ApoE4 Non-Carrier) 20
• 6.4 Factors Affecting Sales of AAB-001 21
• 6.4.1 Disease Modifying Potential 21
• 6.4.2 First in Immunotherapy Class 21
• 6.4.3 Patent Expiry of Existing Marketed Drugs 21
• 6.4.4 Clinical Trials for Other Dosage Forms of AAB-001 21
• 6.4.5 Fast Track Regulatory Status with FDA 21
• 6.4.6 Competition with LY2062430 21
• 6.5 Drug Evaluation 22
• 6.5.1 Drug Risk Benefit Score 22
• 6.5.2 Intensity of Competition 22
• 6.6 Sales Forecast 23
• 6.6.1 Target Patient Pool for AAB-001 23
• 6.6.2 Dosing 23
• 6.6.3 Market Penetration 23
• 6.6.4 Sales Projections of AAB-001 25

7 Appendix 34

• 7.1 Market Definitions 34
• 7.2 Abbreviations 34
• 7.3 Research Methodology 34
• 7.3.1 Coverage 35
• 7.3.2 Secondary Research 35
• 7.3.3 Forecasting 35
• 7.3.4 Number of Patients Approved to Take the Drug 35
• 7.3.5 Net Penetration of Drug 36
• 7.3.6 Net Annual Dosing 36
• 7.3.7 Annual Cost of Therapy 36
• 7.4 Drug Sales Estimates Model 36
• 7.5 Contact Us 37
• 7.6 Disclaimer 37
• 7.7 Sources 37

List of Tables

1.1 List of Tables

• Table 1: Alzheimer's disease, World, Major Pipeline Products in Phase III 10
• Table 2: Mild Stage Alzheimer's disease, Abilities Affected and Their Typical Symptoms 13
• Table 3: Moderate Stage Alzheimer's disease, Abilities Affected and Their Typical Symptoms 14
• Table 4: Severe Stage Alzheimer's disease, Abilities Affected and Their Typical Symptoms 14
• Table 5: Non-pharmacological Approaches for Behavioural Symptoms and Mood Disorders 17
• Table 6: Experimental Disease Modifying Drugs in Phase III for Alzheimer's disease 18
• Table 7: AAB-001, Phase II, Clinical Trial Results 20
• Table 8: AAB-001, Alzheimer's disease, Drug Risk Benefit Score 22
• Table 9: AAB-001, Alzheimer's disease, Global, Sales Forecasts ($m), 2014-2022 25
• Table 10: AAB-001, Alzheimer's disease, The US, Sales Forecasts ($m), 2014-2022 26
• Table 11: AAB-001, Alzheimer's disease, UK, Sales Forecasts ($m), 2015-2022 27
• Table 12: AAB-001, Alzheimer's disease, France, Sales Forecasts ($m), 2015-2022 28
• Table 13: AAB-001, Alzheimer's disease, Germany, Sales Forecasts ($m), 2015-2022 29
• Table 14: AAB-001, Alzheimer's disease, Italy, Sales Forecasts ($m), 2015-2022 30
• Table 15: AAB-001, Alzheimer's disease, Spain, Sales Forecasts ($m), 2015-2022 31
• Table 16: AAB-001, Alzheimer's disease, Japan, Sales Forecasts ($m), 2015-2022 32

List of Figures

1.2 List of Figures

• Figure 1: Brain Affected by Alzheimer's disease 4
• Figure 2: Estimated Lifetime Risks for Alzheimer's disease by Age and Sex, The US 6
• Figure 3: Estimated Number of Cases of Alzheimer's disease (million), The US 6
• Figure 4: Changes in Selected Causes of Death, The US, 2000-2008 7
• Figure 5: Alzheimer's Disease, Global, Market Size Forecasts ($bn), 2011-2022 11
• Figure 6: Drug Model Diagram of AAB-001 23
• Figure 7: AAB-001, Alzheimer's disease, Global, Sales Forecasts ($m), 2014-2022 25
• Figure 8: AAB-001, Alzheimer's disease, The US, Sales Forecasts ($m), 2014-2022 26
• Figure 9: AAB-001, Alzheimer's disease, UK, Sales Forecasts ($m), 2015-2022 27
• Figure 10: AAB-001, Alzheimer's disease, France, Sales Forecasts ($m), 2015-2022 28
• Figure 11: AAB-001, Alzheimer's disease, Germany, Sales Forecasts ($m), 2015-2022 29
• Figure 12: AAB-001, Alzheimer's disease, Italy, Sales Forecasts ($m), 2015-2022 30
• Figure 13: AAB-001, Alzheimer's disease, Spain, Sales Forecasts ($m), 2015-2022 31
• Figure 14: AAB-001, Alzheimer's disease, Japan, Sales Forecasts ($m), 2015-2020 32
• Figure 15: AAB-001, Alzheimer's disease, Sales Distribution by Country (%), 2022 33
• Figure 16: Patients Approved for the Drug 36